A Phase II Exploratory Study to Identify Biomarkers Predictive of Clinical Response to Regorafenib in Patients With Metastatic Colorectal Cancer Who Have Failed First-line Therapy
Phase of Trial: Phase II
Latest Information Update: 23 Aug 2017
At a glance
- Drugs Regorafenib (Primary)
- Indications Colorectal cancer
- Focus Biomarker; Pharmacodynamics
- 16 Aug 2017 Planned End Date changed from 1 Dec 2017 to 1 Feb 2018.
- 16 Aug 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Feb 2018.
- 04 Jul 2015 Trial design presented at the 17th World Congress on Gastrointestinal Cancer.